LivaNova PLC (NASDAQ:LIVN) Stock Has Consensus Price Target of $87.75

Key Points

• LivaNova has a “Moderate Buy” consensus rating from 11 analysts, including seven buys, three holds and one strong buy. The average 12-month price target is $87.75, with recent targets ranging from $85 to $93.
• The company exceeded quarterly expectations, reporting EPS of $1.26 versus the $1.09 consensus and revenue of $390.59 million versus $380.50 million. Revenue increased 10.8% year over year.
• LivaNova shares opened at $80.21, up 1.6%, while institutional investors own 97.64% of the stock. Company insiders sold 7,450 shares worth approximately $591,839 over the past 90 days.

LivaNova PLC (NASDAQ:LIVN - Get Free Report) has received a consensus rating of "Moderate Buy" from the eleven brokerages that are currently covering the stock, Marketbeat.com reports. Three investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating on the company. The average 1 year price target among brokers that have covered the stock in the last year is $87.75.

A number of analysts recently issued reports on LIVN shares. Barclays upgraded LivaNova to a "strong-buy" rating in a research report on Wednesday, October 7th. Stifel Nicolaus set a $85.00 target price on shares of LivaNova in a research note on Wednesday, August 5th. Piper Sandler reiterated an "overweight" rating and set a $90.00 price target (up from $87.00) on shares of LivaNova in a report on Wednesday, September 2nd. Weiss Ratings raised shares of LivaNova from a "hold (c+)" rating to a "buy (b-)" rating in a research note on Tuesday, October 27th. Finally, Needham & Company LLC upped their target price on LivaNova from $81.00 to $93.00 and gave the company a "buy" rating in a research note on Wednesday, August 5th.

LivaNova Stock Up 1.6%

LIVN opened at $80.21 on Tuesday. The company has a quick ratio of 1.21, a current ratio of 1.45 and a debt-to-equity ratio of 0.22. The firm has a 50 day moving average price of $78.52 and a 200-day moving average price of $73.00. LivaNova has a twelve month low of $48.82 and a twelve month high of $85.76. The stock has a market capitalization of $4.42 billion, a price-to-earnings ratio of 23.73 and a beta of 0.87.

LivaNova (NASDAQ:LIVN - Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The company reported $1.26 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.09 by $0.17. LivaNova had a return on equity of 16.35% and a net margin of 12.82%. The company had revenue of $390.59 million during the quarter, compared to the consensus estimate of $380.50 million. During the same period in the previous year, the company posted $1.05 EPS. The firm's revenue was up 10.8% on a year-over-year basis. Equities research analysts forecast that LivaNova will post 3.78 earnings per share for the current year.

Insider Buying and Selling at LivaNova

In related news, Director Brooke Story sold 2,300 shares of the business's stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of $81.42, for a total value of $187,266.00. Following the completion of the transaction, the director owned 7,488 shares of the company's stock, valued at $609,672.96. The trade was a 23.50% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Francesco Bianchi sold 3,500 shares of the company's stock in a transaction on Thursday, September 10th. The stock was sold at an average price of $78.01, for a total value of $273,035.00. Following the sale, the director owned 4,434 shares of the company's stock, valued at $345,896.34. This trade represents a 44.11% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 7,450 shares of company stock worth $591,839 over the last 90 days. 0.35% of the stock is currently owned by company insiders.

Institutional Trading of LivaNova

Several large investors have recently bought and sold shares of the stock. Alamar Capital Management LLC acquired a new stake in shares of LivaNova in the third quarter worth approximately $1,814,000. Covestor Ltd boosted its holdings in LivaNova by 135.1% in the 3rd quarter. Covestor Ltd now owns 1,300 shares of the company's stock valued at $99,000 after purchasing an additional 747 shares during the last quarter. Vise Technologies Inc. raised its position in LivaNova by 40.3% in the third quarter. Vise Technologies Inc. now owns 3,915 shares of the company's stock valued at $299,000 after purchasing an additional 1,124 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al lifted its position in LivaNova by 6.9% in the third quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 52,691 shares of the company's stock valued at $4,031,000 after buying an additional 3,400 shares during the last quarter. Finally, Gibbs Wealth Management lifted its holdings in shares of LivaNova by 7.0% in the 3rd quarter. Gibbs Wealth Management now owns 16,011 shares of the company's stock worth $1,225,000 after acquiring an additional 1,054 shares during the last quarter. Hedge funds and other institutional investors own 97.64% of the company's stock.

LivaNova Company Profile

LivaNova PLC NASDAQ: LIVN is a medical technology company that develops and manufactures devices and therapies for patients with neurological and cardiovascular conditions. Its products are used by hospitals, physicians and other healthcare providers in markets around the world.

The company's Neuromodulation business is best known for VNS Therapy, which uses an implanted device to deliver electrical stimulation to the vagus nerve. The therapy is used primarily for drug-resistant epilepsy and treatment-resistant depression, subject to applicable regulatory approvals.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.